Zoe Price

Research Interests

Cancer Cell Biology Cancer Biology and Clinical Oncology Biochemistry and Cell Biology Biochemistry & Molecular Biology Chemotherapy

Dr Zoe Price

Research Associate

Centre for Cancer Biology

College of Health

Eligible to supervise Masters and PhD (as Co-Supervisor) - email supervisor to discuss availability.

Dr Zoe Price is an early career researcher in the Gene Regulation in Cancer research group at the Centre for Cancer Biology. Her research focuses on alternative splicing variants that drive prostate cancer progression and the development of castration-resistant prostate cancer. Her work aims to better understand the molecular mechanisms underpinning treatment resistance and to identify pro-tumourigenic splice isoforms with therapeutic potential.
 
Dr Price completed her PhD through a joint doctoral program between the University of Adelaide and Nagoya University. Her doctoral research investigated how different molecular weights of hyaluronan influence ovarian cancer stem cell signalling pathways and contribute to chemotherapy resistance. This work provided new insights into the role of extracellular matrix components in cancer progression and therapeutic response.

Date Position Institution name
2026 - ongoing Research Associate University of Adelaide
2025 - 2025 Research Associate University of South Australia
2023 - 2024 Research Assistant South Australian Health and Medical Research Institute
2018 - 2018 Research Assistant University of Adelaide

Date Institution name Country Title
2024 University of Adelaide Australia Jointly-Awarded PhD program between the University of Adelaide and Nagoya University
2017 - 2017 University of Adelaide Australia Honours Degree of Bachelor of Health and Medical Sciences
2013 - 2015 University of Adelaide Australia Bachelor of Biomedical Science (Biochemistry and Immunology and Virology)

Year Citation
2026 Lokman, N. A., Macpherson, A. M., Thompson, A. R., Price, Z. K., Goonetilleke, L., Condina, M. R., . . . Ricciardelli, C. (2026). Proteomics analysis of serum extracellular vesicle identifies UCHL1 as a potential therapeutic target for high grade serous ovarian cancer. British Journal of Cancer, 134(2), 195-207.
DOI
2025 Noye, T. M., Mittal, P., Price, Z. K., Fewster, A., Williams, G., Pukala, T. L., . . . Ricciardelli, C. (2025). Identification of Proteins Associated with Ovarian Cancer Chemotherapy Resistance Using MALDI-MSI. International Journal of Molecular Sciences, 26(12), 5893.
DOI
2025 Khetan, R., Lokman, N. A., Eldi, P., Price, Z. K., Oehler, M. K., Brooks, D. A., . . . Albrecht, H. (2025). Protease-Activated Receptor F2R Is a Potential Target for New Diagnostic/Prognostic and Treatment Applications for Patients with Ovarian Cancer. International Journal of Molecular Sciences, 26(17), 8529.
DOI Scopus3 WoS3 Europe PMC3
2025 Shah, M. V., Hung, K., Baranwal, A., Kutyna, M. M., Al-Kali, A., Toop, C., . . . Hiwase, D. K. (2025). Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutations. Blood Advances, 9(13), 3370-3380.
DOI Scopus10 WoS11 Europe PMC10
2025 Price, Z. K., Lokman, N. A., Morrison, J., Mhlanga, S. N., Sugiyama, M., Koya, Y., . . . Ricciardelli, C. (2025). Identification of Sphingosine Kinase 1 as a Novel Protein Regulated by High Molecular Weight Hyaluronan in Ovarian Cancer.. J Cell Mol Med, 29(9), e70574.
DOI
2023 Varricchio, A., Khan, S., Price, Z. K., Davis, R. A., Ramesh, S. A., & Yool, A. J. (2023). Pharmacological Inhibition of Membrane Signaling Mechanisms Reduces the Invasiveness of U87-MG and U251-MG Glioblastoma Cells In Vitro. Cancers, 15(4), 1-20.
DOI Scopus16 WoS14 Europe PMC13
2023 Price, Z. K., Lokman, N. A., Sugiyama, M., Koya, Y., Yoshihara, M., Oehler, M. K., . . . Ricciardelli, C. (2023). Disabled-2: a protein up-regulated by high molecular weight hyaluronan has both tumor promoting and tumor suppressor roles in ovarian cancer. Cellular and Molecular Life Sciences, 80(11), 1-18.
DOI Scopus7 WoS6 Europe PMC6
2022 Leung, D., Price, Z. K., Lokman, N. A., Wang, W., Goonetilleke, L., Kadife, E., . . . Ahmed, N. (2022). Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial–mesenchymal transition interlinked with reprogrammed metabolism. Journal of Translational Medicine, 20(1), 556-1-556-23.
DOI Scopus29 WoS29 Europe PMC31
2022 Price, Z. K., Lokman, N. A., Yoshihara, M., Kajiyama, H., Oehler, M. K., & Ricciardelli, C. (2022). Disabled-2 (DAB2): A Key Regulator of Anti- and Pro-Tumorigenic Pathways. International Journal of Molecular Sciences, 24(1), 696.
DOI Scopus22 WoS20 Europe PMC21
2019 Lokman, N. A., Price, Z. K., Hawkins, E. K., Macpherson, A. M., Oehler, M. K., & Ricciardelli, C. (2019). 4-Methylumbelliferone inhibits cancer stem cell activation and overcomes chemoresistance in ovarian cancer. Cancers, 11(8), 1-18.
DOI Scopus50 WoS44 Europe PMC39
2019 Mittal, P., Price, Z. K., Lokman, N. A., Ricciardelli, C., Oehler, M. K., Klingler-Hoffmann, M., & Hoffmann, P. (2019). Matrix Assisted Laser Desorption/Ionization Mass Spectrometry Imaging (MALDI MSI) for monitoring of drug response in primary cancer spheroids. Proteomics, 19(21 - 22), e1900146-1-e1900146-4.
DOI Scopus22 WoS20 Europe PMC17
2018 Price, Z., Lokman, N., & Ricciardelli, C. (2018). Differing roles of hyaluronan molecular weight on cancer cell behavior and chemotherapy resistance. Cancers, 10(12), 482-1-482-21.
DOI Scopus78 WoS75 Europe PMC66

Year Citation
2025 Khetan, R., Lokman, N. A., Eldi, P., Price, Z. K., Oehler, M. K., Brooks, D. A., . . . Albrecht, H. (2025). Protease-activated receptor F2R/PAR1 is a potential target for new diagnostic/prognostic and treatment applications for patients with ovarian cancer. In CANCER RESEARCH Vol. 85 (pp. A36). AMER ASSOC CANCER RESEARCH.
DOI
2024 Hung, K., Al-Kali, A., Toop, C., Patnaik, M. M., Price, Z., Kourelis, T., . . . Shah, M. (2024). <i>TP53</i>-Mutated Therapy-Related Myeloid Neoplasms Are Associated with a Long Latency and Are More Prevalent in Patients with Primary Hematological Cancers Compared to Solid Tumors. In BLOOD Vol. 144 (pp. 4594-4595). FL, Orlando: ELSEVIER.
DOI WoS2
2024 Hiwase, D., Price, Z., Kok, C. H., Kutyna, M., Singhal, D., Shanmuganathan, N., . . . Scott, H. S. (2024). Pathogenic Germline Variants in the DNA Damage Repair Pathway Are Enriched in Patients with Hematologic Malignancies with Prior Exposure to Cytotoxic Therapies Compared to Patients with Multiple Cancers without Prior Exposure. In BLOOD Vol. 144 (pp. 4596-4597). FL, Orlando: ELSEVIER.
DOI
2024 Shah, M., Hung, K., Baranwal, A., Price, Z., Al-Kali, A., Toop, C., . . . Hiwase, D. (2024). The 66th ASH Annual Meeting Abstract Abstracts. In BLOOD Vol. 144 (pp. 3214). ELSEVIER.

Connect With Me

External Profiles

Other Links